Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasirox
Deferasiroxum
Brand Names
Sandoz Deferasirox
Deferasirox Accord
Auro-deferasirox (type J)
Taro-deferasirox (type J)
Deferasirox oral
Deferasirox Oral Granules
Taro-deferasirox
Deferasirox (type J)
PMS-deferasirox (type J)
Jamp Deferasirox (type J)
Deferasorox
PMS-deferasirox
Deferasirox Mylan
Teva-deferasirox (type J)
Jadenu
Apo-deferasirox (type J)
Exjade
Teva-deferasirox
Deferasirox
Sandoz Deferasirox (type J)
Apo-deferasirox
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682